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Abstract
Background: Despite the epidemiological evidence about the relationship between diabetes, mortality and
cardiovascular disease, information about the population impact of uncontrolled diabetes is scarce. We aimed to
estimate the attributable risk associated with HbA1c levels for all-cause mortality and cardiovascular hospitalization.
Methods: Prospective study of subjects with diabetes mellitus using electronic health records from the universal
public health system in the Valencian Community, Spain 2008–2012. We included 19,140 men and women aged
30 years or older with diabetes who underwent routine health examinations in primary care.
Results: A total of 11,003 (57%) patients had uncontrolled diabetes defined as HbA1c ≥6.5%, and, among those,
5325 participants had HbA1c ≥7.5%. During an average follow-up time of 3.3 years, 499 deaths, 912 hospitalizations
for coronary heart disease (CHD) and 786 hospitalizations for stroke were recorded. We observed a linear and increasingly
positive dose-response of HbA1c levels and CHD hospitalization. The relative risk for all-cause mortality and CHD and stroke
hospitalization comparing patients with and without uncontrolled diabetes was 1.29 (95 CI 1.08,1.55), 1.38 (95 CI 1.20,1.59)
and 1.05 (95 CI 0.91, 1.21), respectively. The population attributable risk (PAR) associated with uncontrolled diabetes was
13.6% (95% CI; 4.0–23.9) for all-cause mortality, 17.9% (95% CI; 10.5–25.2) for CHD and 2.7% (95% CI; − 5.5-10.8) for stroke
hospitalization.
Conclusions: In a large general-practice cohort of patients with diabetes, uncontrolled glucose levels were associated with
a substantial mortality and cardiovascular disease burden.
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Introduction
Prolonged exposure to hyperglycemia results in vascular
damage [1]. The association between chronic hypergly-
cemia and cardiovascular complications, however, is not
fully understood [2]. The HbA1c level is an indicator of
the average blood glucose concentrations over the
preceding 2–3 months and is used as a biomarker of
diabetes control in clinical practice [3]. There is much
evidence on the role of hyperglycemia as a cardiovascu-
lar disease (CVD) risk factor, sudden death [4], mortality
in myocardial infarction [5] and mortality in critically ill
patients [6], despite the fact that elevated HbA1c has
shown inconsistent risk stratification, according to
different levels [7, 8]. Observational studies and meta-
analyses report that patients with uncontrolled diabetes,
defined as HbA1c > 6.5%, are at increased risk for CVD
and mortality compared to patients with controlled dia-
betes [7, 8]. Moreover, post hoc analyses from the
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Action to Control Cardiovascular Risk in Diabetes (AC-
CORD) [9]; the Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release Controlled
Evaluation (ADVANCE) [10], and the Veterans Affairs
Diabetes Trial (VADT) [11], suggested different effects
of glycemic control in patients with and without pre-
vious vascular disease. Furthermore, the HbA1c level is
an independent risk factor for CV events, regardless of
the diabetes diagnosis [12–15].
Despite the large number of studies analysing the
prognostic value of HbA1c levels, information about the
population impact associated with uncontrolled diabetes
is scarce. The fraction of mortality and CVD potentially
avoidable by achieving certain HbA1c levels in the popu-
lation of individuals with diabetes has not been evalu-
ated, and can be estimated by using real world data from
Electronic Health Recording (EHR) [16]. Moreover,
EHR-based studies from general-practice settings may
provide a privileged view of the burden of disease as-
sociated to uncontrolled diabetes in the whole popu-
lation. The ESCARVAL-RISK study, based on HER, is
a cohort of beneficiaries of the universal health care
system of the Valencian Community, (Spain), with CV
risk factors, including diabetes, considered by a net-
work of general practice physicians [17–19]. The ob-
jective of the present study was to estimate the
attributable risk of all-cause mortality and CV
hospitalization associated to elevated HbA1c levels in
a cohort of patients with diabetes mellitus from the
ESCARVAL-RISK study.
Materials and methods
Study population and baseline data collection
The sample was recruited from beneficiaries of the
Valencian Health Agency’s universal health care sys-
tem. The Valencian Community is a Mediterranean
region located on the East-coast of Spain, with a
population of 3,205,724 people older than 30 years in
2007. Total population data was extracted using the
health information exchange function of ABUCASIS
for the period of time between 1st January 2008 and
31st December 2012. ABUCASIS includes information
on patient demographics, medications, vital status,
past medical history and laboratory data, among
others. Detailed information about the ESCARVAL-
RISK project and data collection methods has been
previously published [17–19].
Eligible patients for the present study were men and
women with diabetes mellitus and free of CV disease.
Participants were included in the study from 1st January
2008 if they fulfilled the eligibility conditions of a
diagnosis of diabetes as a non-fasting glucose level of
≥200 mg/dl, a recorded physician diagnosis, use of glu-
cose lowering drugs or insulin, or HbA1c ≥ 6.5%.
Subsequently, participants newly diagnosed with these
conditions during the study period were also included.
The ESCARVAL-RISK is an observational study with the
described previously characteristics [17–19]. Patient data
was saved from various occasions and locations when
they had received care, such as in the primary care
physician’s office, as well as other physician specialists,
nurses’ offices, pharmacies, hospitals, and emergency de-
partments. As a result, not all the baseline variables that
were needed to adjust for potential confounding in this
study were available at the exact time of inclusion. We
thus defined 6-month windows around the time of study
inclusion in order to gather complete information on
biochemistry results and blood pressure determinations)
and excluded patient with missing dat. Finally, 19,140
diabetic subjects of both sexes aged 30 years or older
who attended routine health examinations and fulfilled
eligibility criteria were selected from the total population
database. The STROBE chart is in Fig. 1.
Cardiovascular risk factors definition
Body mass index (BMI) was calculated by dividing mea-
sured weight in kilograms by measured height in metres
squared. Obesity was defined as a BMI ≥30 kg/m2. Blood
pressure was measured up to three times on the same
day in a sitting position and hypertension was defined as
an office mean systolic blood pressure ≥ 140 mmHg, a
mean diastolic blood pressure ≥ 90 mmHg, a recorded
physician diagnosis, or antihypertensive medication use.
Serum total cholesterol was measured enzymatically
using the Cholesterol High Performance reagent (Roche
Diagnostics). High density-lipoprotein (HDL) cholesterol
was measured using a direct HDL reagent (Roche
Fig. 1 Flow-chart of the study population
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Diagnostics). Low density-lipoprotein LDL cholesterol was
calculated by using the Friedwald formula, considering the
triglyceride levels. High cholesterol was defined as a serum
total cholesterol > 200 mg/dL, recorded diagnosis or
medication use. HbA1c was assessed by the labs of
different hospitals of the Valencia Community using High
performance Liquid Chromatography (HPLC).
Mortality and hospitalization follow-up
ESCARVAL-RISK participants were followed for all-
cause mortality or the first episode of hospitalization for
myocardial infarction or stroke until 31st December
2012. Causes of hospitalization were recorded using
codes of the International Classification of Diseases, 9th
Revision. Vital status was determined by matching
ESCARVAL records and death certificates from the
Spanish National Death Index. Mortality included all
causes of death. Cause-specific hospitalization was de-
fined as the first hospital admission for CHD (ICD-9
codes 410–414), and stroke (ICD-9 codes 430–438, 444).
Time to event was calculated for each individual as the
difference between the date of the inclusion into the
study and the date of the hospital admission, the date of
death, or 31st December 2012, whichever occurred first.
A minimum follow-up period of one year was required.
Confidentiality and ethics requirements
Patients’ data collected from the ABUCASIS system dur-
ing the study were documented and pseudo-anonymized.
The data generated during the study was handled accor-
ding to Spanish Law 5/1999 and corresponding to
European norms. The study was conducted according to
the standards of the International Guidelines for Ethical
Review of Epidemiological Studies (Council for International
Organizations of Medical Sciences-CIOMS-Geneva, 1991)
and the recommendations of the Spanish Society of Epi-
demiology about the review of ethical aspects of epidemio-
logical research. The ESCARVAL-RISK study was reviewed
and approved by the Committee for Ethics and Clinical Tri-
als of the Center for Public Health Research (DGSP-CSISP).
Statistical analysis
HbA1c levels were normally distributed and cut-offs for
HbA1c categories and other quantiles used in the ana-
lysis were based on the distribution in the study sample.
In descriptive analyses, we used generalised linear models to
estimate means and proportions of participants’ characteris-
tics, overall and by HbA1c categories. We also estimated,
age and sex-adjusted rates for mortality and CV
hospitalization end-points using Poisson regression for indi-
vidual data with over-dispersion correction. Multi-adjusted
rate differences were estimated from semi-parametric Aalen
additive hazard models. To graphically display non-linear re-
lationships, we used restricted quadratic splines with knots
at the 20th, 50th and 80th percentiles of HbA1c distribution.
Statistical models were adjusted for potential confounders.
Population attributable risks (PARs) for high HbA1c were
calculated by using the standard formula PAR = 1 – ΣjΣi pij
/ RRi| j [17, 18]. In this formula, the subscript i denotes one
of two categories of HbA1c levels (with each participant
classified as above or below the cut-off being used to calcu-
late the PAR, respectively), the subscript j is an index for all














Age, years; mean 65.1 (0.1) 65.4 (0.2) 66.2 (0.2) 66 (0.2) 66.2 (0.2) 62.9 (0.2) < 0.001
Men; % 54.3 (0.4) 54.8 (0.8) 50 (0.8) 51.4 (0.9) 53.3 (1) 59 (0.7) < 0.001
Obesity; % 49.6 (0.4) 47.4 (0.8) 51.5 (0.8) 49.3 (0.9) 49.7 (1) 50.1 (0.7) 0.098
BMI, kg/m2; mean 30.4 (0) 30.2 (0.1) 30.6 (0.1) 30.4 (0.1) 30.5 (0.1) 30.5 (0.1) 0.05
Former smoking; % 23.4 (0.3) 24 (0.7) 23.2 (0.7) 22.6 (0.7) 22.9 (0.9) 23.8 (0.6) 0.875
Current smoking; % 21.6 (0.3) 18.5 (0.6) 18.4 (0.6) 20.1 (0.7) 20.5 (0.8) 27.8 (0.6) < 0.001
Glucose lowering medication; % 51.8 (0.4) 38.8 (0.7) 45.6 (0.8) 52 (0.9) 60 (1) 62.8 (0.7) < 0.001
Hypertension; % 83.2 (0.3) 83.8 (0.6) 84.1 (0.6) 84.4 (0.6) 83.6 (0.8) 81 (0.5) < 0.001
Antihypertensive medication; % 49 (0.4) 50.4 (0.8) 50.2 (0.8) 52.4 (0.9) 50.3 (1) 44.3 (0.7) < 0.001
Systolic blood pressure, mmHg; mean 138 (0.1) 136.1 (0.3) 137 (0.3) 138.3 (0.3) 138.8 (0.4) 139.9 (0.3) < 0.001
Diastolic blood pressure, mmHg; mean 78.6 (0.1) 78 (0.2) 78.3 (0.2) 78.7 (0.2) 78.3 (0.2) 79.4 (0.1) < 0.001
High cholesterol; % 16.7 (0.3) 18.1 (0.6) 17.2 (0.6) 16.8 (0.7) 16.8 (0.8) 15 (0.5) < 0.001
Total cholesterol, mg/dL; mean 197.5 (0.3) 195.5 (0.6) 197 (0.7) 196.3 (0.7) 194.3 (0.8) 201.8 (0.6) < 0.001
HDL-cholesterol, mg/dL; mean 48.9 (0.1) 50.3 (0.2) 49.9 (0.2) 49.4 (0.2) 48.6 (0.3) 46.8 (0.2) < 0.001
LDL-cholesterol, mg/dL; mean 116.6 (0.2) 116.1 (0.5) 116.3 (0.5) 115.3 (0.6) 113.7 (0.7) 119.3 (0.5) < 0.001
Lipid lowering medication; % 38 (0.3) 35.6 (0.7) 39.2 (0.8) 40.1 (0.9) 40.7 (1) 36.6 (0.7) 0.458
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strata obtained after cross-classifying the study sample for
all adjusted covariates, pij is the proportion of cases over all
cases in the study population in each stratum after
cross-classifying the dichotomous HbA1c categories and all
adjusted covariates, and RRi|j is the adjusted hazard ratio
for the endpoint of interest comparing participants below
and above the HbA1c cut-off in stratum j of covariates,
from Cox proportional hazards regression. We calculated
adjusted PARs for HbA1c > 6.5% from separate models
fully adjusted for age (restricted quadratic splines with 5
knots), sex, smoking status (never, former, current), obesity
(no, yes), hypertension (no, yes), chronic kidney disease (no,
yes), anti-hypertensive medication (no, yes), glucose




The mean age was 65.1 years and 54.3% were males. At
baseline, 49.6% participants were obese (average BMI
30.4 kg/m2), 83.2% participants had hypertension and
16.7% participants showed total cholesterol > 200 mg/dl,
(among those, 38% were receiving lipid lowering drugs).
11,003 (57%) patients had uncontrolled diabetes defined as
HbA1c ≥6.5%, and, among those, 5325 participants had
HbA1c ≥7.5%. Patients were treated with insulin, 8.3%, and
43.5% with different oral glucose lowering agents. The main
characteristics of the study population by HbA1c levels are
shown in Table 1. Participants with increasing HbA1c levels
showed increasing current smoking and glucose lowering
medication status and decreasing HDL cholesterol levels.
Fig. 2 Age and Sex-adjusted rates (events/10,000 person-years) of all-cause mortality and CVD hospitalization by quartile of HbA1c
Table 2 Age and Sex-adjusted rates (events/10,000 person-years) of all-cause mortality and CVD hospitalization by quartile of HbA1c












Median (range), mg/dL 5.6 (4.6, 5.9) 5.6 (6, 6.4) 6.7 (6.5, 6.9) 7.2 (7, 7.4) 8.4 (7.5, 12.6)
All-cause mortality
Cases (person-year) 116 (15,346.42) 80 (12,801.36) 72 (11,233.22) 60 (8174.11) 171 (17,893.89)
Rate 72.1 59.6 60.7 68.8 104.8 < 0.001
CHD hospitalization
Cases (person-year) 169 (14,979.12) 154 (12,477.02) 155 (10,951.90) 123 (7936.55) 311 (17,329.30)
Rate 110.8 122.6 139.0 150.8 185.3 < 0.001
Stroke hospitalization
Cases (person-year) 161 (15,025.62) 166 (12,480.03) 126 (11,002.67) 90 (8016.53) 243 (17,442.46)
Rate 104.9 128.6 109.1 106.3 150.6 0.004
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Dose-response associations
During an average follow-up of 3.3 years, the EHR
recorded 499 deaths, 912 hospitalizations for CHD and
786 hospitalizations for stroke. The age and sex-adjusted
rates and events/10,000 person-years for all-cause
mortality and CVD hospitalization by HbA1c levels are
shown in Table 2 and Fig. 2. We observed a fairly linear
and increasingly positive dose-response of CHD
hospitalization by HbA1c levels (Table 2, Fig. 3, panel 2).
For all-cause mortality, however, the dose-response by
HbA1c levels was non-linear (Fig. 3, panel 1). For stroke
hospitalization, the dose response was statistically sig-
nificant only in the higher range of HbA1c distribution
(Fig. 3, panel 3).
Burden of disease associated to HbA1c level
In additive hazard models, the absolute risk differences
for CHD hospitalization also progressively increased
from 11.41 events/10,000 person-years for HbA1c levels
between 6 and 6.5%, to 70.26 events/10,000 person-years
for HbA1c levels greater than 7% (Table 3). The relative
risk for all-cause mortality and CHD and stroke
hospitalization comparing patients with and without un-
controlled diabetes was 1.29 (95 CI 1.08,1.55), 1.38 (95
CI 1.20,1.59) and 1.05 (95 CI 0.91, 1.21), respectively.
The corresponding population attributable risk (PAR)
associated with uncontrolled diabetes was 13.6% (95%
CI; 4.0–23.9) for all-cause mortality, 17.9% (95% CI;
10.5–25.2) for CHD and 2.7% (95% CI; − 5.5-10.8) for
stroke hospitalization (Table 4).
Discussion
In a large cohort of individuals with diabetes from a
Mediterranean region in Spain, glucose control assessed
Fig. 3 Adjusted Odds Ratios (95% CI) of Mortality and morbidity by
Glycated Hemoglobin levelsThe curve represents adjusted rate ratio
(RR) of mortality (panel 1), CHD hospitalization (panel 2) and stroke
hospitalization (panel 3) by glycated hemoglobin levels, based on
restricted quadratic splines with knots at the 10th, 50th, and 90th
percentiles (5.6%, 6.7% and 8.9%, respectively) of the glycated
hemoglobin distribution. The reference value (RR = 1) was set at
5.6% of the Glycated Hemoglobin. RRs were adjusted for age
(restricted quadratic splines with 5 knots), sex, smoking status (never,
former, current), obesity (no, yes), hypertension (no, yes), chronic
kidney disease (no, yes), HDL cholesterol ≤40 for men and≤ 50 for
women (no, yes), LDL ≥ 130 mg/dL (no, yes), anti-hypertensive
medication (no, yes), glucose lowering medication (no, yes), lipid
lowering medication (no, yes). For a given value (%) of glycated
hemoglobin distribution, the corresponding RR is interpreted as the
expected change in the rate of mortality and CVD hospitalization,
associated to changing glycated hemoglobin from a given value, to
the reference (6.5%). For example, model estimates suggest that the
RR for mortality of participants in the 90th percentile of glycated
hemoglobin (8.9%) is 80% higher, compared to participants in the
Reference (6.5%).
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by HbA1c levels was positively related to the risk of
all-cause mortality, as well as hospitalization by CHD,
starting with HbA1c levels greater than ~ 6%. The
association with stroke hospitalization, however, was only
significant in the higher range of HbA1c levels. The frac-
tion of potentially avoidable deaths associated with having
HbA1c below 6.5% was 14%. The corresponding fraction
of avoidable CHD hospitalizations was 18% (Table 5).
The present study was conducted in a population with a
country-specific low CV risk profile as referenced by the
SCORE study [20], even though the prevalence of diabetes
is 13.8% [21]. In the whole Valencian Community terri-
tory, the EHR associated with the public general-practice
setting has a 92% coverage of the population living in the
area [22]. Every patient has a unique personal identifica-
tion number which guarantees the interoperability of the
EHRs. Thus, administrative data, including all prescrip-
tions and dispensation of subsidized treatments for dia-
betes and hospitalization events are linked to the database
that integrates all the health care interventions and proce-
dures that the patients received. Therefore, this study
includes information on baseline risk factors and follow–
up for mortality and CV hospitalizations from essentially
all adults with diabetes mellitus in the region who had
their HAb1a levels measured by the public health system
during the study period.
The present study supports that the risk of death and
CHD hospitalization is related to glucose-control and
points to the substantial potential for prevention associ-
ated to lowering HbA1c levels. Despite the epidemio-
logical evidence about the relationship between glucose
control, assessed by HbA1c, and CV events, randomized
clinical trials did not show a benefit of better
glucose-control in reducing risk. Thus, evidence was not
sufficient to generate strong recommendations for clin-
ical practice. In fact, the evidence was graded IIa/C in
the ACCF/AHA guidelines for assessment of CV risk in
asymptomatic adults [23] and by the ESC-EARD [24].
Recent revisions of guidelines from Scientific Societies
moved away from uniform recommendations and
towards a more nuanced patient-centered approach to
HbA1c therapeutic targets [25]. It is possible that a
minimum study duration and a minimum gain in HbA1c
reduction are necessary to drive a relevant risk reduction
in CV risk [26]. In the absence of conclusive evidence
from RCTs, observational epidemiological studies using
real world data [27] might provide additional useful
information to clarify the attributable risk of glucose
control in CV risk.
The population impact of uncontrolled diabetes in the
present study is displayed in three ways. First, we show
age and sex-adjusted absolute rates for mortality or
hospitalization for CHD or stroke by HbA1c subgroups
of interest. The rate of CHD hospitalization shows a
progressive increment from the lowest to the highest
level, while the rate of stroke hospitalization is less con-
stant across the HbA1c categories. In agreement with
the present study, a meta-analysis showed that 1%
HbA1c reduction was associated with a lowered major
CV risk by glycemic control, but was not associated
with lowered stroke and death risks [7]. Studies with
strong association with stroke come from Taiwan [28]
and Korea [8], in which the risk of stroke is high
compared with Caucasians. For all-cause mortality,
but not for CHD or stroke hospitalization, a U-shape
curve was observed, such as that in the UK GPRD
and ARIC, studies that showed increased risk of
all-cause death with both lower and higher HbA1c
levels [13, 29]. However, the U-shaped curve was not
confirmed in other studies such as the Swedish
National Diabetes Register cohort [30].
Second, we calculated the multi-adjusted rate differences
in mortality or hospitalizations (also termed “attributable
risk”), comparing patients with progressively increasing
HbA1c levels to HbA1c levels lower than 6%. This can be
interpreted as the average annual increase in mortality and
CV disease hospitalization risk on an absolute scale attribu-
table to HbA1c categories adjusting for potential
confounders. In both all-cause mortality and stroke
hospitalization the attributable risks were only statistically
Table 5 Main messages on the mortality and cardiovascular
disease burden of uncontrolled diabetes in a registry-based
cohort: the ESCARVAL-risk study
Main messages
There is much evidence on the role of hyperglycemia as a
cardiovascular disease
The HbA1c level is used as a biomarker of diabetes control in clinical
practice and is an independent risk factor for CV events, regardless of
the diabetes diagnosis
Information about the population impact associated with
uncontrolled diabetes is scarce
In a large cohort of individuals with diabetes, HbA1c levels was
positively related to the risk of all-cause mortality, as well as
hospitalization by CHD, starting with HbA1c levels > 6%.
The fraction of potentially avoidable deaths associated with having
HbA1c below 6.5% was 14% and the corresponding fraction of
avoidable CHD hospitalizations was 18%.
Table 4 Population attributable risk of all-cause mortality and










RR 1.29 (1.08, 1.55) 1.38 (1.2, 1.59) 1.05 (0.91, 1.21)
PAR % 13.62 (3.96, 22.90) 17.90 (10.53, 25.20) 2.64 (−5.51, 10.76)
Model is fully adjusted for age (restricted quadratic splines with 5 knots), sex,
smoking status (never, former, current), obesity (no, yes), hypertension (no,
yes), chronic kidney disease (no, yes), anti-hypertensive medication (no, yes),
glucose lowering medication (no, yes), lipid lowering medication (no, yes). The
prevalence of glycated hemoglobin > 6.5% was 57.78%
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significant at HbA1c > 7.5%. For CHD hospitalization,
however, the attributable risk became borderline statistically
significant at the 6.5% cut-off, but displayed a progressive in-
crease across HbA1c categories. Moreover, at the higher
range of HbA1c levels, the attributable risk for CHD
hospitalization doubles. These results have not been pre-
viously reported in other cohorts of patients with diabetes,
but support the current target levels of HbA1c < 7% recom-
mended by the guidelines of the American Diabetes Associ-
ation [31].
Third, we estimated the adjusted PAR associated to
uncontrolled diabetes defined as HbA1c > 6.5%, which
represents the estimated fraction of deaths that would be
avoided in the population. This assumes that the effects
are causal and that other risk factors remained unchanged,
and therefore suggests that strict diabetes control could
relevantly diminish the CV disease burden of diabetes.
More studies are needed to confirm the findings.
The study needs to be considered within its strengths
and limitations. The main limitation of the present study
is the lack of information about the duration and
progression of the CV risk factors. Thus, some degree of
residual confounding cannot be discarded. Another limi-
tation is the absence of HbA1c follow-up data; therefore,
it was not possible to test the potential role of HbA1c
individual trajectories on mortality and CV risk. In
addition, the ascertainment of CHD and stroke hos-
pitalizations was performed mainly through hospital
discharge codes, which may have led to the under-ascer-
tainment of cases that perhaps were not severe enough
to warrant hospitalization. Finally, it is possible that
findings from this Mediterranean cohort are not
generalizable to other populations. However, the EHR
system of the Valencian Community (ABUCASIS), which
is the framework for the ESCARVAL project, allowed
the monitoring of a population-based sample of indivi-
duals with diabetes throughout their experience in a
general practice system. While the follow-up time in this
study was not long, the large sample size, however,
provided enough power and a valuable frame to assess
the attributable risk of mortality and CHD and stroke
associated to diabetes control in the short term. This
provides a common scale for comparing the potential
population-level impact of interventions for disease
prevention.
Conclusions
In conclusion, in a large general-practice cohort of
patients with diabetes, uncontrolled diabetes was associ-
ated with a substantial mortality and CV disease burden.
While our results support a potential benefit of decrea-
sing HbA1c levels below the traditional 6.5% threshold
in patients with diabetes, additional studies are needed
to confirm these findings.
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